Cerapedics completed a US $22MM financing. Proceeds will support continued launch of i-FACTOR™ Peptide Enhanced Bone Graft and a second Level I investigational device exemption (IDE) human clinical study.
The round was led by KCK Group, a family investment fund.
Cerapedics received FDA Premarket Approval in 2015 for use of i-FACTOR in anterior cervical discectomy and fusion, and was the first PMA-approved bone graft with this indication. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion.
Cerapedics completed a US $22MM financing. Proceeds will support continued launch of i-FACTOR™ Peptide Enhanced Bone Graft and a second Level I investigational device exemption (IDE) human clinical study.
The round was led by KCK Group, a family investment fund.
Cerapedics received FDA Premarket Approval in 2015 for use of i-FACTOR in...
Cerapedics completed a US $22MM financing. Proceeds will support continued launch of i-FACTOR™ Peptide Enhanced Bone Graft and a second Level I investigational device exemption (IDE) human clinical study.
The round was led by KCK Group, a family investment fund.
Cerapedics received FDA Premarket Approval in 2015 for use of i-FACTOR in anterior cervical discectomy and fusion, and was the first PMA-approved bone graft with this indication. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion.
Copy to clipboard 
